Samrat Pharmachem informs about newspaper publication

Samrat Pharmachem Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 530125 | NSE:

02 Sep 2026 Evaluate

Samrat Pharmachem has informed that the 34th Annual General Meeting (AGM) of Members of Samrat Pharmachem will be held on Wednesday, September 23, 2026 at 1.00 pm IST through Video Conference (VC) / Other Audio Visual Means (OAVM) to transact the businesses, as set out in the Notice convening AGM. The Company has sent Annual Report for the financial year 2025-26 along with the Notice convening AGM, through electronic mode on Thursday, August 27, 2026 to the Members whose email addresses are registered with the Company and/ or Depositories in accordance with the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. The Annual Report along with the Notice convening the AGM is also available on the website of the Company at www.samratpharmachem.com. Pursuant to the provisions of Section 91 of the Companies Act, 2013 (Act) and the applicable rules framed therein that the Register of Members and Share Transfer Books of the Company will remain closed from Sunday, September 20, 2026 to Tuesday, September 22, 2026 for the purpose of 34th AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Members are provided with the facility to cast their votes on all resolutions as set forth in the Notice convening the AGM using electronic voting system (e-voting). provided by MUFG Intime India. The voting rights of Members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Wednesday, September 16, 2026 ('cut-off date'). The remote e-voting period commences on Sunday, September 20, 2026 at 9:00 AM (IST) and will end on Wednesday, September 22, 2026 at 5:00 PM (IST).

The above information is a part of company's filings submitted to BSE.

Samrat Pharmachem Share Price

237.50 0.65 (0.27%)

04-Sep-2026 14:12 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1899.10
Dr. Reddys Labs.	1158.00
Cipla	1380.55
Lupin	2110.00
Zydus Lifesciences	1129.10
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

Address : The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.